Results 131 to 140 of about 950,345 (395)

Concomitant oral tyrosine kinase inhibitors and bisphosphonates in advanced renal cell carcinoma with bone metastases [PDF]

, 2012
Benoit Beuselinck, Pascal Wolter, Alexandra Karadimou, Réza Elaidi, Herlinde Dumez, Anne Rogiers, Thomas Van Cann, Ludo Willems, J.J. Body, J. Berkers, Hendrik Van Poppel, Evelyne Lerut, Philip R. Debruyne, Robert Paridaens, Patrick Schöffski   +14 more
openalex   +1 more source

Phosphorylation of CLEC-2 is dependent on lipid rafts, actin polymerization,secondary mediators, and Rac [PDF]

, 2010
The C-type lectin-like receptor 2 (CLEC-2)activates platelets through Src and Syk tyrosine kinases via a single cytoplasmic YxxL motif known as a hem immunoreceptor tyrosine-based activation motif (hemITAM).Here, we demonstrate using sucrose gradient ...
Alice Y. Pollitt, Atkinson, Barrow, Beata Grygielska, Bertrand Leblond, Bodin, Bodin, Boggon, Christou, Colonna, Eble, Ezumi, Fuller, He, Hooley, Hughes, Huysamen, Johannes A. Eble, Kerrigan, Laurent Désiré, Lee, Locke, May, McCarty, Pestina, Piechulek, Pierce, Pleines, Quek, Sancho, Schacht, Shutes, Simons, Sobanov, Spalton, Steve P. Watson, Suzuki-Inoue, Suzuki-Inoue, Tolias, Walliser, Watson, Watson, Wonerow, Wonerow, Xu   +44 more
core   +1 more source

Biomaterial Strategies for Targeted Intracellular Delivery to Phagocytes

Advanced Functional Materials, EarlyView.
Phagocytes are essential to a functional immune system, and their behavior defines disease outcomes. Engineered particles offer a strategic opportunity to target phagocytes, harnessing inflammatory modulation in disease. By tuning features like size, shape, and surface, these systems can modulate immune responses and improve targeted treatment for a ...
Kaitlyn E. Woodworth, Neal I. Callaghan, Locke Davenport Huyer   +2 more
wiley   +1 more source

Celecoxib inhibits proliferation and survival of chronic myelogeous leukemia (CML) cells via AMPK-dependent regulation of β-catenin and mTORC1/2. [PDF]

, 2016
CML is effectively treated with tyrosine kinase inhibitors (TKIs). However, the efficacy of these drugs is confined to the chronic phase of the disease and development of resistance to TKIs remains a pressing issue.
Calabretta, Bruno, Canonico, Pier Luigi, Condorelli, Fabrizio, De Dominici, Marco, Genazzani, Armando A, Gnemmi, Ilaria, Mariani, Samanta A., Minassi, Alberto, Minieri, Valentina, Riva, Beatrice, Salomoni, Paolo   +10 more
core   +2 more sources

A Smart Bio‐Battery Facilitates Diabetic Bone Defect Repair Via Inducing Macrophage Reprogramming and Synergistically Modulating Bone Remodeling Coupling

Advanced Functional Materials, EarlyView.
This research presents a novel implantable bio‐battery, GF‐OsG, tailored for diabetic bone repair. GF‐OsG generates microcurrents in high‐glucose conditions to enhance vascularization, shift macrophages to the M2 phenotype, and regulate immune responses.
Nanning Lv, Haifu Sun, Wenxiang Tang, Yonggang Li, Zhonglai Qian, Lihui Hong, Chong Chen, Hongye Li, Jiaxiang Bai, Yusen Qiao, Mingming Liu   +10 more
wiley   +1 more source

Subsequent chemotherapy reverses acquired tyrosine kinase inhibitor resistance and restores response to tyrosine kinase inhibitor in advanced non-small-cell lung cancer

BMC Cancer, 2011
Background Patients with advanced or metastatic non-small cell lung cancer (NSCLC) can develop acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors (TKIs) erlotinib and gefitinib.
Sun Jin, Zhang Zhiyuan, Wang Tongshan, Chen Xiaofen, Guo Renhua, Shu Yongqian   +5 more
doaj   +1 more source

Prognostic significance of additional chromosomal abnormalities at the time of diagnosis in patients with chronic myeloid leukemia treated with frontline tyrosine kinase inhibitors [PDF]

, 2017
Ahmad Alhuraiji, Hagop M. Kantarjian, Prajwal Boddu, Farhad Ravandi, Gautam Borthakur, Courtney D. DiNardo, Naval Daver, Tapan M. Kadia, Naveen Pemmaraju, Sherry Pierce, Guillermo Garcia‐Manero, William G. Wierda, Srđan Verstovšek, Elias Jabbour, Jorge E. Cortés   +14 more
openalex   +1 more source

Gold Nanoclusters as Dual Agents for Engineering Tumor Vascular Leakiness and Performing Photothermal Therapy

Advanced Functional Materials, EarlyView.
Many cancer nanotherapeutics, while potent, suffer from the inability to escape from the tumor vasculature, especially in the absence of endothelial permeability. In this work, ultrasmall gold nanoclusters could engineer nanomaterials induced endothelial leakiness (NanoEL) and harness strong NIR induced photothermal characteristics to suppress tumor ...
Nengyi Ni, Kuoran Xing, Bihan Zhang, Baoteng Wang, Yinglu Chen, Jianping Xie, Xiao Sun, Jinping Wang, David Tai Leong   +8 more
wiley   +1 more source

Combined targeting of STAT3 and STAT5: a novel approach to overcome drug resistance in chronic myeloid leukemia

Haematologica, 2017
In chronic myeloid leukemia, resistance against BCR-ABL1 tyrosine kinase inhibitors can develop because of BCR-ABL1 mutations, activation of additional pro-oncogenic pathways, and stem cell resistance.
Karoline V. Gleixner, Mathias Schneeweiss, Gregor Eisenwort, Daniela Berger, Harald Herrmann, Katharina Blatt, Georg Greiner, Konstantin Byrgazov, Gregor Hoermann, Marina Konopleva, Islam Waliul, Abbarna A. Cumaraswamy, Patrick T. Gunning, Hiroshi Maeda, Richard Moriggl, Michael Deininger, Thomas Lion, Michael Andreeff, Peter Valent   +18 more
doaj   +1 more source

HER2-L755S mutation induces hyperactive MAPK and PI3K-mTOR signaling, leading to resistance to HER2 tyrosine kinase inhibitor treatment [PDF]

, 2019
Jiayao Li, Qian Xiao, Bao Yi, Wenyu Wang, Jian-Yuan Goh, Panpan Wang, Qiang Yu   +6 more
openalex   +1 more source